Precision Biologics is pleased to announce a continuation of encouraging clinical data from its ongoing Phase 1-2a study utilizing its novel monoclonal antibody NPC-1C. The data will be presented by the investigators from Duke University at the ASCO GI meeting on January 17, 2014 in SF, CA. We previously reported results at the 2013 ASCO annual meeting using the initial formulation of NPC-1C (NEO-101) in patients with advanced pancreatic and colorectal cancer, who progressed on standard therapies.
Help employers find you! Check out all the jobs and post your resume.
